Morgan Stanley Reiterates Overweight on Eli Lilly, Citing New Platform Potential

Morgan Stanley has reaffirmed its 'Overweight' rating on Eli Lilly (LLY), highlighting the substantial growth potential of the company's new platform. This positive outlook is based on anticipated future developments.